Beta Glucan Gut Microbiome Randomized Trial: What the Evidence Says

Quick Answer

Beta Glucan Gut Microbiome Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Owing to the limited number of human and mechanistic studies, we recommend a multidisciplinary approach integrating expertise in food processing, analytical chemistry, and microbiology to further elucidate their potential to improve health through gut microbiome modulation. [Keigler Johanna I. (2026); evidence level 3]
• Specifically, a longitudinal study examined for changes to the gut microbiota and metabolites of 15 healthy subjects who consumed 4.5 g CG daily for three weeks.The intake of CG was associated with changes in the relative abundance of nine microbial genera, including significant increases in, andand decreases inandIncreases in the fecal levels of the SCFAs butyric, caproic, and isovaleric acids were also reported. [Keigler Johanna I. (2026); evidence level 3]
• By interacting with innate pattern recognition receptors (PRRs), including Dectin-1 and Toll-like receptors (TLRs), expressed on gut-associated lymphoid tissue (GALT) and immune cells, β-1,3-glucans regulate both innate and adaptive immune responses. [Samiksha Fnu (2026); evidence level 4]
• Table 2 A summary of β-glucans derived from different fungal sources and their associated therapeutic properties is provided in. [Samiksha Fnu (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For beta glucan gut microbiome randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Keigler Johanna I. (2026). Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods. DOI: 10.1080/19490976.2026.2677948. PMCID: PMC13217915. PMID: 42198987. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13217915/
• Samiksha Fnu (2026). Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. DOI: 10.3390/nu18111794. PMCID: PMC13258535. PMID: 42280437. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258535/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.